thalidomide has been researched along with AIDS-Related Opportunistic Infections in 31 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
AIDS-Related Opportunistic Infections: Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Sixteen HIV-infected patients with clinical and histological diagnosis of oral recurrent aphthous ulcerations received randomly an 8-week course of either thalidomide or placebo, with an initial oral dosage of 400 mg/d for 1 week, followed by 200 mg/d for 7 weeks." | 6.69 | Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial. ( Esquivel-Pedraza, L; Gonzalez-Guevara, M; Ponce-de-Leon, S; Ramirez-Amador, VA; Reyes-Teran, G; Sierra-Madero, JG, 1999) |
| "Curative treatment of aggressive Kaposi sarcoma (KS) with conventional chemotherapy in human immunodeficiency virus (HIV)-infected patients remains difficult." | 5.39 | Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma. ( Burg, S; Crickx, B; Di Lucca, J; Feldman, J; Joly, V; Lariven, S; Marinho, E; Maubec, E; Peytavin, G; Raymond, E; Sarda-Mantel, L; Steff, M, 2013) |
| " Thalidomide (Synovir), developed by Celgene, has received limited approval for the treatment of leprosy." | 3.70 | FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration. ( Highleyman, L, 1998) |
| " Others report on the use of thalidomide or IL-10 for curtailing or suppressing tumor necrosis factor alpha in coincident HIV and tuberculosis patients." | 3.69 | Or is it the host, sir? ( Mascolini, M, 1996) |
| " Sixteen HIV-infected patients with clinical and histological diagnosis of oral recurrent aphthous ulcerations received randomly an 8-week course of either thalidomide or placebo, with an initial oral dosage of 400 mg/d for 1 week, followed by 200 mg/d for 7 weeks." | 2.69 | Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial. ( Esquivel-Pedraza, L; Gonzalez-Guevara, M; Ponce-de-Leon, S; Ramirez-Amador, VA; Reyes-Teran, G; Sierra-Madero, JG, 1999) |
| "Thalidomide was evaluated for its in vitro activity against Encephalitozoon species by using the MRC-5 cell system." | 2.40 | Lack of in vitro antimicrosporidian activity of thalidomide. ( Drancourt, M; Ridoux, O, 1999) |
| "Curative treatment of aggressive Kaposi sarcoma (KS) with conventional chemotherapy in human immunodeficiency virus (HIV)-infected patients remains difficult." | 1.39 | Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma. ( Burg, S; Crickx, B; Di Lucca, J; Feldman, J; Joly, V; Lariven, S; Marinho, E; Maubec, E; Peytavin, G; Raymond, E; Sarda-Mantel, L; Steff, M, 2013) |
| "Management of relapsing or refractory immune reconstitution inflammatory syndromes (IRISs) despite corticosteroid therapy is yet to be defined." | 1.38 | Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS. ( Brunel, AS; Le Moing, V; Lortholary, O; Makinson, A; Montes, B; Reynes, J; Rubbo, PA; Tuaillon, E, 2012) |
| "Thalidomide has shown promise in treating wasting and contact information is provided for a compassionate use program." | 1.30 | Approaches to the AIDS Wasting Syndrome. ( Corcoran, C, 1998) |
| "Thalidomide trials have been slow to recruit, therefore buyers clubs are working to make the drug available through their services." | 1.29 | Thalidomide and HIV: several possible uses. ( Smith, D, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 23 (74.19) | 18.2507 |
| 2000's | 2 (6.45) | 29.6817 |
| 2010's | 6 (19.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kwon, HY | 1 |
| Han, YJ | 1 |
| Im, JH | 1 |
| Baek, JH | 1 |
| Lee, JS | 1 |
| Balasko, A | 1 |
| Keynan, Y | 1 |
| Steff, M | 1 |
| Joly, V | 1 |
| Di Lucca, J | 1 |
| Feldman, J | 1 |
| Burg, S | 1 |
| Sarda-Mantel, L | 1 |
| Peytavin, G | 1 |
| Marinho, E | 1 |
| Crickx, B | 1 |
| Raymond, E | 1 |
| Lariven, S | 1 |
| Maubec, E | 1 |
| Fourcade, C | 1 |
| Mauboussin, JM | 1 |
| Lechiche, C | 1 |
| Lavigne, JP | 1 |
| Sotto, A | 1 |
| Di Lucca-Christment, J | 1 |
| Jacobelli, S | 1 |
| Gressier, L | 1 |
| Plantier, F | 1 |
| Laude, H | 1 |
| Rozenberg, F | 1 |
| Rosenberg, F | 1 |
| Morini, JP | 1 |
| Dallot, A | 1 |
| Avril, MF | 1 |
| Dupin, N | 1 |
| Brunel, AS | 1 |
| Reynes, J | 1 |
| Tuaillon, E | 1 |
| Rubbo, PA | 1 |
| Lortholary, O | 1 |
| Montes, B | 1 |
| Le Moing, V | 1 |
| Makinson, A | 1 |
| Shetty, K | 1 |
| Weinroth, SE | 1 |
| Parenti, DM | 1 |
| Simon, GL | 1 |
| Sharpstone, D | 1 |
| Rowbottom, A | 1 |
| Nelson, M | 1 |
| Gazzard, B | 1 |
| Kaplan, G | 1 |
| Vicente, T | 1 |
| Ortega, A | 1 |
| Muñoz, P | 1 |
| Diaz, MD | 1 |
| Bouza, E | 1 |
| DeVincenzo, JP | 1 |
| Burchet, SK | 1 |
| Bassetti, S | 1 |
| Courvoisier, S | 1 |
| Itin, P | 1 |
| Surawicz, CM | 2 |
| Fife, K | 1 |
| Howard, MR | 1 |
| Gracie, F | 1 |
| Phillips, RH | 1 |
| Bower, M | 1 |
| Rubio, FA | 1 |
| Herranz, P | 1 |
| Robayna, G | 1 |
| Peña, JM | 1 |
| Contreras, F | 1 |
| Casado, M | 1 |
| Ridoux, O | 1 |
| Drancourt, M | 1 |
| Ramirez-Amador, VA | 1 |
| Esquivel-Pedraza, L | 1 |
| Ponce-de-Leon, S | 2 |
| Reyes-Teran, G | 1 |
| Gonzalez-Guevara, M | 1 |
| Sierra-Madero, JG | 1 |
| Smith, D | 1 |
| Grunfeld, C | 1 |
| James, JS | 1 |
| Mascolini, M | 1 |
| Corcoran, C | 1 |
| Highleyman, L | 1 |
| Taiwo, BO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study[NCT04273529] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-02-20 | Not yet recruiting | ||
| The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study[NCT04273581] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-02-18 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for thalidomide and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Shedding light on IRIS: from Pathophysiology to Treatment of Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome in HIV-Infected Individuals.
Topics: Adrenal Cortex Hormones; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Clinical Tri | 2019 |
Wasting syndrome in AIDS: pathophysiologic mechanisms and therapeutic approaches.
Topics: Acetylcysteine; Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Body Comp | 1995 |
Lack of in vitro antimicrosporidian activity of thalidomide.
Topics: AIDS-Related Opportunistic Infections; Analysis of Variance; Animals; Anti-HIV Agents; Dose-Response | 1999 |
4 trials available for thalidomide and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Cytokine regulation of disease progression in leprosy and tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Cytokines; Erythema Nodosum; HIV-1; Humans; Immunity, Cellula | 1994 |
Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre.
Topics: Adult; AIDS-Related Opportunistic Infections; Dermatologic Agents; Herpesvirus 8, Human; Humans; Mal | 1998 |
Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Double-Blind Method; Humans; Male; Or | 1999 |
Thalidomide effective in treating AIDS-related mouth ulcers.
Topics: Adult; AIDS-Related Opportunistic Infections; Esophageal Diseases; Female; Humans; Immunosuppressive | 1996 |
24 other studies available for thalidomide and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Two cases of immune reconstitution inflammatory syndrome in HIV patients treated with thalidomide.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Brain Edema; Do | 2019 |
Two cases of immune reconstitution inflammatory syndrome in HIV patients treated with thalidomide.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Brain Edema; Do | 2019 |
Two cases of immune reconstitution inflammatory syndrome in HIV patients treated with thalidomide.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Brain Edema; Do | 2019 |
Two cases of immune reconstitution inflammatory syndrome in HIV patients treated with thalidomide.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Brain Edema; Do | 2019 |
Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma.
Topics: AIDS-Related Opportunistic Infections; Angiogenesis Inhibitors; Antiretroviral Therapy, Highly Activ | 2013 |
Thalidomide in the treatment of immune reconstitution inflammatory syndrome in HIV patients with neurological tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active | 2014 |
Anogenital pseudotumoral herpes and HIV infection: a new challenge for diagnosis and treatment.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Carcinoma, Squamous Cell; Cidofovir; | 2012 |
Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiretroviral The | 2012 |
Thalidomide for recurrent aphthous ulcerations.
Topics: AIDS-Related Opportunistic Infections; Humans; Recurrence; Stomatitis, Aphthous; Thalidomide | 2003 |
The treatment of microsporidial diarrhoea with thalidomide.
Topics: AIDS-Related Opportunistic Infections; Animals; Diarrhea; Humans; Male; Microsporida; Microsporidios | 1995 |
In vitro activity of thalidomide against Mycobacterium avium complex.
Topics: AIDS-Related Opportunistic Infections; Humans; In Vitro Techniques; Mycobacterium avium Complex; Myc | 1993 |
Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral aphthous ulcers.
Topics: AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Child, Preschool; Esophageal Diseases; | 1996 |
[Oral ulcers in HIV infection].
Topics: Adult; AIDS-Related Opportunistic Infections; Diagnosis, Differential; Humans; Immunosuppressive Age | 1997 |
Thalidomide for AIDS diarrhea?
Topics: AIDS-Related Opportunistic Infections; Animals; Antiprotozoal Agents; Diarrhea; Humans; Microsporida | 1997 |
New hope for AIDS patients.
Topics: AIDS-Related Opportunistic Infections; Animals; Humans; Intestinal Diseases, Parasitic; Microsporida | 1998 |
Thalidomide.
Topics: Abnormalities, Drug-Induced; Adjuvants, Immunologic; AIDS-Related Opportunistic Infections; Anti-Inf | 1998 |
Perforating folliculitis: report of a case in an HIV-infected man.
Topics: Adult; AIDS-Related Opportunistic Infections; Biopsy; Dermatologic Agents; Folliculitis; Hair Follic | 1999 |
Thalidomide and HIV: several possible uses.
Topics: AIDS-Related Opportunistic Infections; Cachexia; Clinical Trials as Topic; HIV Infections; Humans; N | 1995 |
State of the art in wasting: an interview with Carl Grunfeld, PhD. Interview by Jeff Getty.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Animals; Cachexia; Endocr | 1995 |
Thalidomide for wasting syndrome: progress toward compromise.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cachexia; Dose-Response R | 1995 |
Or is it the host, sir?
Topics: Adjuvants, Immunologic; AIDS-Related Opportunistic Infections; Anti-Infective Agents; CD8-Positive T | 1996 |
Weight loss update.
Topics: AIDS-Related Opportunistic Infections; Appetite Stimulants; Female; Growth Hormone; HIV Infections; | 1996 |
The thalidomide comeback.
Topics: AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV Infection | 1998 |
Approaches to the AIDS Wasting Syndrome.
Topics: AIDS-Related Opportunistic Infections; Anabolic Agents; Appetite Stimulants; Dronabinol; Exercise; F | 1998 |
Simply stated...are people still wasting?
Topics: AIDS-Related Opportunistic Infections; Appetite Stimulants; Energy Intake; Growth Hormone; HIV Infec | 1998 |
FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration.
Topics: 2-Aminopurine; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; D | 1998 |
Use of thalidomide in HIV infection.
Topics: Adrenal Cortex Hormones; AIDS-Related Opportunistic Infections; HIV Infections; Humans; Recurrence; | 2001 |